HGH Fragment, Modified GRF, Ipamorelin
Also known as HGH Fragment 176-191, hGH Frag 176-191, growth hormone fragment, lipolytic fragment
HGH Fragment 176-191 combined with Modified GRF (CJC-1295 No DAC) and Ipamorelin creates a triple-action body recomposition system that burns fat aggressively while preserving muscle and amplifying growth hormone at multiple levels. The Fragment targets the specific fat-burning region of growth hormone without affecting blood sugar or hormones, Modified GRF triggers natural pulsatile GH release mimicking your body’s youthful pattern, and Ipamorelin amplifies those pulses cleanly.
Route
Subcutaneous injection
Dose range
100 mcg – 500 mcg
Frequency
Frag 1-2x daily; GHRH/GHRP 1x daily
Cycle length
8–12 weeks
Overview
HGH Fragment 176-191 combined with Modified GRF (CJC-1295 No DAC) and Ipamorelin creates a triple-action body recomposition system that burns fat aggressively while preserving muscle and amplifying growth hormone at multiple levels. The Fragment targets the specific fat-burning region of growth hormone without affecting blood sugar or hormones, Modified GRF triggers natural pulsatile GH release mimicking your body’s youthful pattern, and Ipamorelin amplifies those pulses cleanly. Together they can boost GH 10-fold or more, creating dramatic lean tissue gains while melting stubborn belly and thigh fat—results that diet and exercise alone rarely achieve.
The synergistic power lies in three complementary mechanisms converging on optimal body recomposition: Fragment 176-191 directly mobilizes fat for energy, Modified GRF and Ipamorelin elevate anabolic hormones supporting muscle preservation and collagen synthesis. Studies show this blend preserves lean mass during aggressive fat loss better than any single peptide, with users reporting visible abs, fullness in muscles, and transformed composition within 8-12 weeks. Enhanced recovery, deeper sleep, improved cognition, and metabolic flexibility are bonus perks. Ideal for competitive athletes, physique competitors, or anyone hitting a body recomposition wall, nightly injections align with natural GH windows for compounding benefits.
Studied benefits
- This stack focuses on aggressive fat oxidation (HGH Fragment) combined with a highly controlled GH pulse (Modified GRF + Ipamorelin)
- It is effective for body recomposition and metabolic health without significantly affecting blood sugar or appetite
Reported side effects
- Generally well-tolerated
- potential for a temporary "head rush" or flushing immediately after administration and minor swelling at the site of injection
Protocol
Dosing Schedule (Subcutaneous)
Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.
HGH Frag 176-191 + Mod GRF + Ipamorelin Blend
Reconstitute with 3.0 mL bacteriostatic water for precise multi-peptide measurement.
Investigating the combined effect of direct lipolysis (Fragment) and GHRH/GHRP synergy (Mod GRF/Ipamorelin) on adipose tissue reduction.
| Peptide | Standard Dose | Draw at 2.5 mg/mL | Log |
|---|---|---|---|
| HGH Fragment | 250–500 mcg | 20 units (0.2 mL) | + Log |
| Mod GRF / Ipamorelin | 100 mcg each | 4 units (0.04 mL) | + Log |
Frequency
Frag 1-2x daily; GHRH/GHRP 1x daily.
Timing
Must be administered on an empty stomach to avoid insulin interference.
Cycle length
8–12 weeks.
Unit calculator
Set your vial and water; the table above updates.
2.5 mg/mL
10 doses of 500 mcg per vial
At the starting dose (500 mcg × 14/week for a 8-week cycle) you would use about 56 mg, i.e. 12 × 5 mg vials. Higher phases use proportionally more.
Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.
Context
Lifestyle considerations
Follow a nutrient-dense, balanced diet with a focus on timing; the fat-burning effects of the Fragment are significantly enhanced when insulin levels are low. Combine this protocol with regular cardiovascular activity and strength training to capitalize on the improved recovery and metabolic rate. Ensure 7–9 hours of quality sleep to facilitate the deep-recovery processes driven by the growth hormone axis. Maintain optimal hydration and manage stress, as elevated cortisol can counteract the lipolytic benefits and metabolic efficiency of this potent three-part peptide combination.
Evidence
Research summaries
Modified GRF (CJC No DAC) and Ipamorelin Synergy with HGH Frag for Lipolysis
Findings: Enhanced fat mobilization, preserved muscle during cuts, optimized GH/IGF axis.
Modified GRF (CJC shorthand) extends GH pulses; Ipamorelin cleans them; Frag burns fat directly. Combo mimics natural rhythm, spiking lipolysis post-lag. Superior to singles for body comp.
Read the study ↗More references (5)
- HGH Fragment 176-191 Enhances Toxicity of Chitosan Nanoparticles, 2022
- Growth Hormone Secretagogues and IGF-1 Stimulation, 2020
- Safety and Tolerability of Ipamorelin in Human Trials, 2014
- Short-term Administration of Modified GRF 1-29 (Sermorelin), 2006
- Metabolic Studies of the Lipolytic Domain of hGH, 2001
Identification
Chemistry
- common names
- HGH Fragment 176-191, hGH Fragment 176-191, hGH Frag 176-191, growth hormone fragment, lipolytic fragment, fat-burning peptide, AOD9604 analog; Modified GRF (1-29), Mod GRF (1-29), CJC-1295 (No DAC), CJC-1295 without DAC, Modified GHRH (1-29), GRF (1-29) analog, pulsatile CJC-1295, MOD-GRF; Ipamorelin, NNC-26-0161, selective GHS-R1a agonist, growth hormone secretagogue, GHS; Blend Designation: HGH Fragment 176-191/Modified GRF (1-29)/Ipamorelin blend, Fragment 176-191/Mod GRF/Ipamorelin combination, Fragment/GHRH/GHS triple peptide blend, three-component lipolytic and growth hormone secretagogue blend
- cas
- 66004-57-7
- formula
- C₇₈H₁₂₃N₂₃O₂₂S₂
- molecular weight
- 1,799.08–1,799.10 Da (g/mol)
- sequence
- Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe (with disulfide bridge between Cys7 and Cys14)
- source
- Synthetic (laboratory-manufactured)
- biosynthesis
- Non-ribosomal synthesis via chemical peptide synthesis; derived from C-terminal sequence of hGH
- type
- Linear peptide with internal disulfide bond linking cysteines at positions 7 and 14, creating cyclic structural constraint
Keep exploring
Related peptides
5-Amino-1MQ
5-amino-1-methylquinolinium · NNMTi
- Route
- Subcutaneous
- Dose
- 2.5 mg – 5 mg
- Cycle
- 10–20 days (based on a single 50 mg vial)
Adipotide (FTPP)
FTPP · Adipotide
- Route
- Subcutaneous
- Dose
- 5 mcg – 20 mcg
- Cycle
- 21–28 days; monitoring of renal markers is standard
AICAR
Acadesine · AICA-Riboside
- Route
- Subcutaneous
- Dose
- 1 mg – 3 mg
- Cycle
- 8–12 weeks
AOD-9604
AOD 9604 · Tyr-hGH fragment 177-191
- Route
- Subcutaneous
- Dose
- 200 mcg – 500 mcg
- Cycle
- 8–12 weeks